The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis

Expert Review of Respiratory Medicine

Volumn 6, Issue 5, 2012, Pages

  Wilson, Robert ^a   MacKlin Doherty, Aislinn ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

antibiotic; bacterial infection; chronic bronchitis; chronic obstructive pulmonary disease; exacerbation; moxifloxacin; quinolone

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ACUTE DISEASE; BACTERIAL INFECTION; BRONCHITIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW;

ACUTE DISEASE; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; BRONCHITIS; CHRONIC DISEASE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES;

EID: 84868285647     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.50     Document Type: Review

References (84)

1. Buist AS, McBurnie MA, Vollmer WM et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 370(9589), 741-750 (2007). (Pubitemid 47321907)
2. Gulsvik A. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch. Chest Dis. 56(3), 261-264 (2001). (Pubitemid 32951968)
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064), 1498-1504 (1997). (Pubitemid 27216360)
4. Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance-United States 1971-2000. MMWR Surveill. Summ. 51, 1-16 (2002).
5. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. NCHS Data Brief 63, 1-8 (2011).
6. Organisation for Economic Co-operation and Development. Health at a Glance 2009: OECD Indicators. OECD Publishing, Paris, France (2009).
7. Miravitlles M, Murio C, Guerrero T, Gisbert R; DAFNE Study Group. Decisiones sobre antibioticoterapia y farmacoeconomía en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121(5), 1449-1455 (2002). (Pubitemid 34499654)
8. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: A 1-year follow-up study. Chest 123(3), 784-791 (2003). (Pubitemid 36315494)
9. Pawels R, Calverty P, Buist AS et al. COPD exacerbations: the importance of a standard defnition. Respir. Med. 98, 99-107 (2004). (Pubitemid 38181126)
10. Nicholson P, Anderson P. The patients' burden; physiological and psychological effects of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45, 25-32 (2000).
11. Llor C, Molina J, Naberan K, Cots JM, Ros F, Miravitlles M; EVOCA Study Group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int. J. Clin. Pract. 62(4), 585-592 (2008). (Pubitemid 351348035)
12. Miravitlles M. Prevention of exacerbation of COPD with pharmacotherapy. Eur. Respir. Rev. 19, 119-126 (2010).
13. Miravitlles M. Health economic consequences of COPD exacerbations. In: Chronic Obstructive Pulmonary Disease Exacerbations. Wedzicha JA, Martinez FJ (Eds). Informa Healthcare, NY, USA, 225-232 (2009).
14. Anthonisen NR, Manfreda J, Warren CP, Hershfeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (2), 196-204 (1987). (Pubitemid 17009877)
15. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur. Respir. J. 23(6), 932-946 (2004). (Pubitemid 38807371)
16. Papi A, Bellettato CM, Braccioni F et al. Infections and airway infammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care. Med. 173, 1114-1121 (2006). (Pubitemid 43726892)
17. De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J. Clin. Virol. 46(2), 129-133 (2009).
18. de Marco R, Accordini S, Cerveri I et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 175(1), 32-39 (2007). (Pubitemid 46105306)
19. Wilson R. Bacteria, antibiotics and COPD. Eur. Respir. J. 17(5), 995-1007 (2001). (Pubitemid 32600350)
20. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 8(8), 1333-1338 (1995).
21. Hill AT, Campbell EJ, Hill SL et al. Association between airway bacterial load and markers of airways infammation in patients with stable chronic bronchitis. Am. J. Med. 108, 288-295 (2000).
22. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117 (6), 1638-1645 (2000). (Pubitemid 30413357)
23. Allegra L, Blasi F, Diano P et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir. Med. 99(6), 742-747 (2005). (Pubitemid 40631301)
24. Soler N, Agustí C, Angrill J, Puig De la Bellacasa J, Torres A. Bronchoscopic validation of the signifcance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62(1), 29-35 (2007). (Pubitemid 46101763)
25. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117(5 Suppl. 2), 380S-385S (2000). (Pubitemid 30314471)
26. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359(22), 2355-2365 (2008).
27. Hurst JR, Vestbo J, Anzueto A et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363(12), 1128-1138 (2010).
28. Soler N, Agustí C, Angrill J, Puig De la Bellacasa J, Torres A. Bronchoscopic validation of the signifcance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62, 29-35 (2007). (Pubitemid 46101763)
29. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus infuenzae in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170(3), 266-272 (2004). (Pubitemid 38971411)
30. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347(7), 465-471 (2002). (Pubitemid 34879333)
31. Soler N, Ewig S, Torres A et al. Airway infammation and bronchial microbial patterns in patients with stable chronic obstructive disease. Eur. Respir. J. 14, 1015-1022 (1999).
32. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway infammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173(9), 991-998 (2006).
33. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway infammation and health status in clinical stable COPD. Eur. Respir. J. 23(5), 685-691 (2004). (Pubitemid 38618136)
34. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial infammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58(8), 680-685 (2003). (Pubitemid 36976277)
35. Sethi S, Jones PW, Theron MS et al.; PULSE Study Group. Pulsed moxifoxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Respir. Res. 11, 10 (2010).
36. Wilson R, Nisbet M. Antibiotic therapy at COPD exacerbations. In: Chronic Obstructive Pulmonary Disease Exacerbations. Wedzicha JA, Martinez FJ (Eds). Lung Biology Health and Disease, Informa Healthcare, NY, USA, 251-265 (2009).
37. Wilson R, Kubin R, Ballin I et al. Five day moxifoxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 44(4), 501-513 (1999). (Pubitemid 29490621)
38. Wilson R, Allegra L, Huchon G et al.; MOSAIC Study Group. Short-term and long-term outcomes of moxifoxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125(3), 953-964 (2004). (Pubitemid 38367286)
39. Van Parys BA, Sethi S, Lode H et al. L-1156. Patient reported outcome (PRO) measure in AECOPD. Preliminary fndings: observational clinical study. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007
40. Miravitlles M, Ferrer M, Pont A et al. Characteristics of a population of COPD patients identifed from a population-based study. Focus on previous diagnosis and never smokers. Respir. Med. 99(8), 985-995 (2005). (Pubitemid 40796541)
41. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10, 3B-32B (2003). (Pubitemid 37192994)
42. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratifcation in the management of acute bacterial exacerbations of chronic bronchitis: the role of levofoxacin 750mg. Eur. Respir. J. 25, 1001-1010 (2005) (Pubitemid 40823774)
43. Societé de Pneumologie de Langue Francaise. Guidelines for the clinical management of COPD. Exacerbations/acute respiratory failure: antibi other apy. Rev. Mal. Respir. 20, 565-568 (2003).
44. Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of frst-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. Chest 132(2), 447-455 (2007). (Pubitemid 47282375)
45. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11 (4), 256-280 (2005). (Pubitemid 40443832)
46. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42(6), 410-425 (1996). (Pubitemid 26379929)
47. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone mediated bacterial death. Antimicrob. Agents Chemother. 52, 385-392 (2008).
48. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifoxacin: A comparison with other fuoroquinolones. J. Antimicrob. Chemother. 45(5), 583-590 (2000). (Pubitemid 30255636)
49. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44(5), 681-688 (2007).
50. Stass H, Dalhoff A, Kubitza D, Schühly U. Pharmacokinetics, safety and tolerability of ascending single does of moxifoxacin, a new 8-methoxyqinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42, 2060-2065 (1998). (Pubitemid 28363093)
51. Sullivan JY, Woodruff M, Lettieri J et al. Pharmacokinetics of a once daily dose of moxifoxacin (bay12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chermother. 43, 2793-2797 (1999). (Pubitemid 29519568)
52. Scheld WM. Maintaining fuoroquinolone class effcacy: review of infuencing factors. Emerging Infect. Dis. 9(1), 1-9 (2003). (Pubitemid 36110195)
53. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifoxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fbre-optic bronchoscopy. J. Antimicrob. Chemother. 44(6), 835-838 (1999).
54. Lister PD, Sanders CC. Pharmacodynamics of moxifoxacin, levofoxacin and sparfoxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 47(6), 811-818 (2001). (Pubitemid 32519829)
55. Stass H, Kubitza D. Profle of moxifoxacin drug interactions. Clin. Infect. Dis. 32(Suppl. 1), S47-S50 (2001).
56. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. Quinolones: action and resistance updated. Curr. Top. Med. Chem. 9(11), 981-998 (2009).
57. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profle of moxifoxacin. Clin. Infect. Dis. 32(Suppl. 1), S51-S63 (2001). (Pubitemid 32506747)
58. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fuoroquinolones: A strategy for avoiding bacterial resistance. Proc. Natl Acad. Sci. USA 94(25), 13991-13996 (1997). (Pubitemid 28009697)
59. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61(3), 377-392 (1997). (Pubitemid 28090230)
60. Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community acquired respiratory tract infections in 2003 to fuoroquinolones and other agents. Int. J. Antimicrob. Agents 30, 345-351 (2007). (Pubitemid 47361718)
61. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short course moxifoxacin therapy for treatment of acute bacterial exacerbation of chronic bronchitis. Resp. Med. 94, 18-27 (2000). (Pubitemid 30113846)
62. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and effcacy of short course (5 day) moxifoxacin vs azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Resp. Med. 94, 2019 (2000).
63. Hautamaki D, Bruya T, Kureishi A et al. Short course (5 day) moxifoxacin versus 7 day levofoxacin therapy for the treatment of acute exacerbations of chronic bronchitis. Today Ther. Trends. 19, 61-73 (2001).
64. Ram FSF, Rodriquez-Roisin R, Granados-Navarrete A. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane. Database. Syst. Rev. 2, CD004403 (2006).
65. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofoxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. Lancet 358(9298), 2020-2025 (2001). (Pubitemid 34084824)
66. Lode H, Eller J, Linnhoff A et al. Levofoxacin versus clarithromycin in chronic obstructive pulmonary disease exacerbation: focus on exacerbation-free interval. Eur. Respir. J. 24, 947-953 (2004). (Pubitemid 39642284)
67. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP; MOSAIC Study Group. Antibiotic treatment and factors infuencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 61(4), 337-342 (2006).
68. Wilson R. Outcome predictors in bronchitis. Chest 108(Suppl. 2), 53S-57S (1995).
69. Wilson R, Anzueto A, Miravitlles M et al. Moxifoxacin vs amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results. Eur. Respir. J. 40(1), 17-27 (2012).
70. Kreis SR, Herrera N, Golzar N, Fuller HD, Heyd A; The Therapeutic Circles Bronchitis Study Group. A comparison of moxifoxacin and azithromycin for the treatment of acute exacerbations of chronic bronchitis. J. Clin. Outcomes. Manag 7, 33-37 (2000).
71. Lorenz J, Thate-Waschke IM, Mast O, et al. Treatment outcomes in exacerbations of chronic bronchitis: comparison of macrolides and moxifoxacin from the patient perspective. J. Int. Med. Res. 29, 74-86 (2001). (Pubitemid 32471872)
72. Grassi C, Casali L, Curti E et al. Effcacy and safety of short course (5 day) moxifoxacin vs 7 day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis. J. Chemother. 14, 597-608 (2002). (Pubitemid 36135415)
73. Miravitlles M, Molina J, Brosa M. Clinical effcacy of moxifoxacin in the treatment of exacerbations of chronic bronchitis: A systematic review and meta-analysis. Arch. Bronchoneumol. 43, 22-28 (2007). (Pubitemid 46232753)
74. Landen H, Möller M, Tillotson GS, Kubin R, Höffken G. Clinical experience in Germany of treating community acquired respiratory infections with the new methoxyfuoroquinolone, moxifoxacin. J. Int. Med. Res. 29, 51-60 (2001). (Pubitemid 32471870)
75. Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials. Clin. Drug. Invest. 23, 439-450 (2003). (Pubitemid 36920516)
76. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin. Drug Invest. 24, 63-72 (2004). (Pubitemid 38316595)
77. Miravitlles M, Anzueto A, Ewig S, Legnani D, Stauch K. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study. Ther. Adv. Respir. Dis. 3(6), 267-277 (2009).
78. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fuoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S144-S157 (2005).
79. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profle or oral and intravenous moxifoxacin: cumulative data from clinical trials and post-marketing studies. Clin. Ther. 26, 940-949 (2004).
80. Tulkens P, Arvis P, Kruesmann F. Clinical safety of moxifoxacin (MFX): an analysis of all 'valid for safety' data from controlled Phase II to Phase IV studies (double blind and open label) performed between 1996 and 2010. Presented at: The 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, UK, 31 March-3 April 2012.
81. Andriole V T, Haverstock DC, Choudhri SH. Retrospective analysis of the profle of oral moxifoxacin in elderly patients enrolled in clinical trials. Drug. Saf. 28, 443-452 (2005). (Pubitemid 40733730)
82. Falegas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fuoroquinolones therapy. Int. J. Antimicrob. Agents 29, 374-379 (2007).
83. Van Bambeke F, Tulkens PM. Safety profle of the respiratory fuoroquinolone moxifoxacin. Comparison with other fuoroquinolones and other antibacterial classes. Drug. Saf. 32(5), 359-378 (2009).
84. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Clin. Micro. Infect. 17(Suppl. 6), E1-E59 (2011).